Clinical Evaluation of Risankizumab-rzaa in the Treatment of Plaque Psoriasis

Risankizumab-rzaa (Skyrizi(®); AbbVie) is a humanized IgG monoclonal antibody directed against interleukin-23p19 (IL-23p19) indicated for the treatment of moderate-to-severe psoriasis in adults who are candidates for systemic therapy or phototherapy. Four pivotal Phase III trials: UltIMMa-1, UltIMMa...

Descripción completa

Detalles Bibliográficos
Autores principales: Reddy, Vidhatha, Yang, Eric J, Myers, Bridget, Liao, Wilson
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6985981/
https://www.ncbi.nlm.nih.gov/pubmed/32158251
http://dx.doi.org/10.2147/JIR.S215196
_version_ 1783491888363339776
author Reddy, Vidhatha
Yang, Eric J
Myers, Bridget
Liao, Wilson
author_facet Reddy, Vidhatha
Yang, Eric J
Myers, Bridget
Liao, Wilson
author_sort Reddy, Vidhatha
collection PubMed
description Risankizumab-rzaa (Skyrizi(®); AbbVie) is a humanized IgG monoclonal antibody directed against interleukin-23p19 (IL-23p19) indicated for the treatment of moderate-to-severe psoriasis in adults who are candidates for systemic therapy or phototherapy. Four pivotal Phase III trials: UltIMMa-1, UltIMMa-2, IMMhance, and IMMvent have demonstrated efficacy and safety in patients with moderate-to-severe plaque psoriasis. This review highlights important findings from these and other clinical trials that have evaluated risankizumab. In addition, we discuss the mechanism of action, pharmacokinetics/pharmacodynamics, dosing recommendations, drug interactions, other potential indications, and ongoing clinical trials.
format Online
Article
Text
id pubmed-6985981
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-69859812020-03-10 Clinical Evaluation of Risankizumab-rzaa in the Treatment of Plaque Psoriasis Reddy, Vidhatha Yang, Eric J Myers, Bridget Liao, Wilson J Inflamm Res Review Risankizumab-rzaa (Skyrizi(®); AbbVie) is a humanized IgG monoclonal antibody directed against interleukin-23p19 (IL-23p19) indicated for the treatment of moderate-to-severe psoriasis in adults who are candidates for systemic therapy or phototherapy. Four pivotal Phase III trials: UltIMMa-1, UltIMMa-2, IMMhance, and IMMvent have demonstrated efficacy and safety in patients with moderate-to-severe plaque psoriasis. This review highlights important findings from these and other clinical trials that have evaluated risankizumab. In addition, we discuss the mechanism of action, pharmacokinetics/pharmacodynamics, dosing recommendations, drug interactions, other potential indications, and ongoing clinical trials. Dove 2020-01-22 /pmc/articles/PMC6985981/ /pubmed/32158251 http://dx.doi.org/10.2147/JIR.S215196 Text en © 2020 Reddy et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Reddy, Vidhatha
Yang, Eric J
Myers, Bridget
Liao, Wilson
Clinical Evaluation of Risankizumab-rzaa in the Treatment of Plaque Psoriasis
title Clinical Evaluation of Risankizumab-rzaa in the Treatment of Plaque Psoriasis
title_full Clinical Evaluation of Risankizumab-rzaa in the Treatment of Plaque Psoriasis
title_fullStr Clinical Evaluation of Risankizumab-rzaa in the Treatment of Plaque Psoriasis
title_full_unstemmed Clinical Evaluation of Risankizumab-rzaa in the Treatment of Plaque Psoriasis
title_short Clinical Evaluation of Risankizumab-rzaa in the Treatment of Plaque Psoriasis
title_sort clinical evaluation of risankizumab-rzaa in the treatment of plaque psoriasis
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6985981/
https://www.ncbi.nlm.nih.gov/pubmed/32158251
http://dx.doi.org/10.2147/JIR.S215196
work_keys_str_mv AT reddyvidhatha clinicalevaluationofrisankizumabrzaainthetreatmentofplaquepsoriasis
AT yangericj clinicalevaluationofrisankizumabrzaainthetreatmentofplaquepsoriasis
AT myersbridget clinicalevaluationofrisankizumabrzaainthetreatmentofplaquepsoriasis
AT liaowilson clinicalevaluationofrisankizumabrzaainthetreatmentofplaquepsoriasis

Ejemplares similares